LEO Pharma Sets Footprint In China Aimed At Dermatology Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Denmark-based dermatology company LEO Pharma is opening a China facility in Shanghai to market its leading anti-psoriasis product Daivobet, the company announced Dec. 8